Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by Artificial Transcription Factors. Issue 3 (5th March 2013)

• Record Type: Journal Article
• Authors: Huisman, Christian; Wisman, G. Bea A.; Kazemier, Hinke G.; van Vugt, Marcel A.T.M.; van der Zee, Ate G.J.; Schuuring, Ed; Rots, Marianne G.
• Is Part Of: Molecular oncology. Volume 7:Issue 3(2013)
• Page Start: 669
• Page End: 679
• Publication Date: 2013-03-05
• Subjects: Methylation biomarkers -- Artificial Transcription Factors -- Tumor suppressor genes -- DNA methylation/epigenetics -- Cellular responses to anticancer drugs -- Novel antitumor agents; Cancer -- Molecular aspects -- Periodicals; 616.994005
• DOI: 10.1016/j.molonc.2013.02.017
• Languages: English
• ISSNs: 1574-7891

Abstract

Abstract : C13ORF18 is frequently hypermethylated in cervical cancer but not in normal cervix and might serve as a biomarker for the early detection of cervical cancer in scrapings. As hypermethylation is often observed for silenced tumor suppressor genes (TSGs), hypermethylated biomarker genes might exhibit tumor suppressive activities upon re‐expression. Epigenetic drugs are successfully exploited to reverse TSG silencing, but act genome‐wide. Artificial Transcription Factors (ATFs) provide a gene‐specific approach for re‐expression of silenced genes. Here, we investigated the potential tumor suppressive role of C13ORF18 in cervical cancer by ATF‐induced re‐expression. Five zinc finger proteins were engineered to bind the C13ORF18 promoter and fused to a strong transcriptional activator. C13ORF18 expression could be induced in cervical cell lines: ranging from >40‐fold in positive (C13ORF18‐unmethylated) cells to >110‐fold in negative (C13ORF18‐methylated) cells. Re‐activation of C13ORF18 resulted in significant cell growth inhibition and/or induction of apoptosis. Co‐treatment of cell lines with ATFs and epigenetic drugs further enhanced the ATF‐induced effects. Interestingly, re‐activation of C13ORF18 led to partial demethylation of the C13ORF18 promoter and decreased repressive histone methylation. These data demonstrate the potency of ATFs to re‐express and potentially demethylate hypermethylated silenced genes. Concluding, we show that C13ORF18 has a TSG function in cervical cancer and may serve as a therapeutic anti‐cancer target. As the amount of epimutations in cancer exceeds the number of gene mutations, ATFs provide promising tools to validate hypermethylated marker genes as therapeutic targets. Highlights: ► Gene‐specific re‐activation of putative TSG C13ORF18 by ATFs. ► Re‐expression of C13ORF18 by ATFs inhibits tumor growth in cervical cancer. ► Targeted reversal of epigenetic marks (DNA and histone methylation). ► Synergistic effects of ATFs with epigenetic drugs. ► Epigenetic regulation C13ORF18 .